Heat Biologics Unveils RapidVax®, A Novel Cellular Vaccine Platform Targeting Known and Unknown Emerging Biological Threats
November 30, 2021 07:30 ET
|
Heat Biologics
Designed for rapid “plug and play” programming and stockpiling against emerging infectious agents and viral mutations Emergence of Omicron and other COVID-19 variants underscores the need for a...
Heat Biologics Provides Third Quarter 2021 Business Update
November 10, 2021 16:05 ET
|
Heat Biologics
DURHAM, N.C., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (“Heat”) (NASDAQ: HTBX), today provided strategic, financial, and operational updates for the third quarter ended September 30,...
Heat Biologics Appoints Paul Tebbey as Senior Vice President of Product Development and Portfolio Strategy
October 06, 2021 07:30 ET
|
Heat Biologics
DURHAM, N.C., Oct. 06, 2021 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (“Heat”) (NASDAQ: HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate...
Heat Biologics CEO to Present at the Cantor Fitzgerald Global Healthcare Conference on September 29th
September 15, 2021 07:30 ET
|
Heat Biologics
DURHAM, N.C., Sept. 15, 2021 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (Nasdaq: HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune...
Heat Biologics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
September 09, 2021 08:30 ET
|
Heat Biologics
DURHAM, N.C., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (Nasdaq: HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune...
Heat Biologics to Provide Corporate Update
August 30, 2021 07:30 ET
|
Heat Biologics
DURHAM, N.C., Aug. 30, 2021 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (“Heat”) (NASDAQ: HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate...
Heat Biologics Unveils Skunkworx Bio, New Drug Discovery Subsidiary
August 26, 2021 08:00 ET
|
Heat Biologics
DURHAM, N.C., Aug. 26, 2021 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (“Heat”) (NASDAQ: HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate...
Heat Biologics Announces Addition of Former US Senator Mark Pryor to Biothreat Advisory Board
August 23, 2021 08:00 ET
|
Heat Biologics
DURHAM, N.C., Aug. 23, 2021 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (“Heat”) (NASDAQ: HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate...
Heat Biologics Announces New Additions to Biothreat Advisory Board
August 19, 2021 09:00 ET
|
Heat Biologics
Former Assistant Secretary of Defense for Nuclear, Chemical & Biological Defense Programs, Andrew C. Weber Expert on Chemical and Biological Weapons, Dr. Gregory Koblentz DURHAM, N.C., Aug. 19,...
Heat Biologics Announces Formation of Biothreat Advisory Board
August 18, 2021 08:00 ET
|
Heat Biologics
DURHAM, N.C., Aug. 18, 2021 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (“Heat”) (NASDAQ: HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate...